Transcatheter aortic valve implantation (from inception to standard treatment): a single-center observational study
Background Treatment of severe aortic stenosis with transcatheter aortic valve implantation (TAVI) was introduced in 2002. Since then, TAVI has become the primary treatment approach worldwide for advanced-age patients and younger patients with severe comorbidities. We aimed to evaluate the changes i...
Published in: | Frontiers in Cardiovascular Medicine |
---|---|
Main Authors: | , , , |
Format: | Article in Journal/Newspaper |
Language: | unknown |
Published: |
Frontiers Media SA
2024
|
Subjects: | |
Online Access: | http://dx.doi.org/10.3389/fcvm.2024.1298346 https://www.frontiersin.org/articles/10.3389/fcvm.2024.1298346/full |
id |
crfrontiers:10.3389/fcvm.2024.1298346 |
---|---|
record_format |
openpolar |
spelling |
crfrontiers:10.3389/fcvm.2024.1298346 2024-02-11T10:06:56+01:00 Transcatheter aortic valve implantation (from inception to standard treatment): a single-center observational study Høydahl, Martin Petter Busund, Rolf Rösner, Assami Kjønås, Didrik 2024 http://dx.doi.org/10.3389/fcvm.2024.1298346 https://www.frontiersin.org/articles/10.3389/fcvm.2024.1298346/full unknown Frontiers Media SA https://creativecommons.org/licenses/by/4.0/ Frontiers in Cardiovascular Medicine volume 11 ISSN 2297-055X Cardiology and Cardiovascular Medicine journal-article 2024 crfrontiers https://doi.org/10.3389/fcvm.2024.1298346 2024-01-26T10:06:12Z Background Treatment of severe aortic stenosis with transcatheter aortic valve implantation (TAVI) was introduced in 2002. Since then, TAVI has become the primary treatment approach worldwide for advanced-age patients and younger patients with severe comorbidities. We aimed to evaluate the changes in patient demographics, complications, and mortality rates within 13 years. Methods This retrospective observational study included 867 patients who underwent TAVI at the University Hospital of North Norway in Tromsø from 2008 to 2021. The 13-year period was divided into period 1 (2008–2012), period 2 (2013–2017), and period 3 (2018–2021). The primary objective was to evaluate the changes in periprocedural (30 days), early (30–365 days), and late mortality rates (>365 days) between the periods. The secondary objective was to evaluate late mortality rates by sex and age groups: <70 years, 70–79 years, 80–89 years, and ≥90 years. Results The periprocedural mortality rates for periods 1, 2, and 3 were 10.3%, 2.9%, and 1.2%, respectively ( P < 0.001). The early mortality rates were 5.6%, 5.8%, and 6.5%, respectively. No significant differences were observed in late mortality by sex or age group (<70, 70–79, and 80–89 years) with a median survival of 5.3–5.6 years. The median survival in patients aged ≥90 years was 4.0 years ( P = 0.018). Conclusion Our findings indicate that most patients are octogenarians, and the burden of their comorbidities should be highly considered compared to their age when evaluating the procedural outcomes. As the incidence of most complications related to TAVI has decreased, the rates of permanent pacemaker implantation remain high. Important advancements in diagnostics, valve technology, and procedural techniques have improved the periprocedural mortality rates; however, early mortality remains unchanged and poses a clinical challenge that needs to be addressed in the future. Article in Journal/Newspaper North Norway Tromsø Frontiers (Publisher) Norway Tromsø Frontiers in Cardiovascular Medicine 11 |
institution |
Open Polar |
collection |
Frontiers (Publisher) |
op_collection_id |
crfrontiers |
language |
unknown |
topic |
Cardiology and Cardiovascular Medicine |
spellingShingle |
Cardiology and Cardiovascular Medicine Høydahl, Martin Petter Busund, Rolf Rösner, Assami Kjønås, Didrik Transcatheter aortic valve implantation (from inception to standard treatment): a single-center observational study |
topic_facet |
Cardiology and Cardiovascular Medicine |
description |
Background Treatment of severe aortic stenosis with transcatheter aortic valve implantation (TAVI) was introduced in 2002. Since then, TAVI has become the primary treatment approach worldwide for advanced-age patients and younger patients with severe comorbidities. We aimed to evaluate the changes in patient demographics, complications, and mortality rates within 13 years. Methods This retrospective observational study included 867 patients who underwent TAVI at the University Hospital of North Norway in Tromsø from 2008 to 2021. The 13-year period was divided into period 1 (2008–2012), period 2 (2013–2017), and period 3 (2018–2021). The primary objective was to evaluate the changes in periprocedural (30 days), early (30–365 days), and late mortality rates (>365 days) between the periods. The secondary objective was to evaluate late mortality rates by sex and age groups: <70 years, 70–79 years, 80–89 years, and ≥90 years. Results The periprocedural mortality rates for periods 1, 2, and 3 were 10.3%, 2.9%, and 1.2%, respectively ( P < 0.001). The early mortality rates were 5.6%, 5.8%, and 6.5%, respectively. No significant differences were observed in late mortality by sex or age group (<70, 70–79, and 80–89 years) with a median survival of 5.3–5.6 years. The median survival in patients aged ≥90 years was 4.0 years ( P = 0.018). Conclusion Our findings indicate that most patients are octogenarians, and the burden of their comorbidities should be highly considered compared to their age when evaluating the procedural outcomes. As the incidence of most complications related to TAVI has decreased, the rates of permanent pacemaker implantation remain high. Important advancements in diagnostics, valve technology, and procedural techniques have improved the periprocedural mortality rates; however, early mortality remains unchanged and poses a clinical challenge that needs to be addressed in the future. |
format |
Article in Journal/Newspaper |
author |
Høydahl, Martin Petter Busund, Rolf Rösner, Assami Kjønås, Didrik |
author_facet |
Høydahl, Martin Petter Busund, Rolf Rösner, Assami Kjønås, Didrik |
author_sort |
Høydahl, Martin Petter |
title |
Transcatheter aortic valve implantation (from inception to standard treatment): a single-center observational study |
title_short |
Transcatheter aortic valve implantation (from inception to standard treatment): a single-center observational study |
title_full |
Transcatheter aortic valve implantation (from inception to standard treatment): a single-center observational study |
title_fullStr |
Transcatheter aortic valve implantation (from inception to standard treatment): a single-center observational study |
title_full_unstemmed |
Transcatheter aortic valve implantation (from inception to standard treatment): a single-center observational study |
title_sort |
transcatheter aortic valve implantation (from inception to standard treatment): a single-center observational study |
publisher |
Frontiers Media SA |
publishDate |
2024 |
url |
http://dx.doi.org/10.3389/fcvm.2024.1298346 https://www.frontiersin.org/articles/10.3389/fcvm.2024.1298346/full |
geographic |
Norway Tromsø |
geographic_facet |
Norway Tromsø |
genre |
North Norway Tromsø |
genre_facet |
North Norway Tromsø |
op_source |
Frontiers in Cardiovascular Medicine volume 11 ISSN 2297-055X |
op_rights |
https://creativecommons.org/licenses/by/4.0/ |
op_doi |
https://doi.org/10.3389/fcvm.2024.1298346 |
container_title |
Frontiers in Cardiovascular Medicine |
container_volume |
11 |
_version_ |
1790604961155907584 |